

# Adriano Lazzarin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8402866/publications.pdf>

Version: 2024-02-01

385  
papers

21,765  
citations

11639

70  
h-index

11601

135  
g-index

387  
all docs

387  
docs citations

387  
times ranked

12326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients. <i>New England Journal of Medicine</i> , 2004, 351, 438-450.	13.9	1,220
2	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 339-354.	13.9	699
3	Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia. <i>New England Journal of Medicine</i> , 2003, 348, 2186-2195.	13.9	676
4	Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 796-806.	6.3	621
5	Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. <i>Lancet</i> , The, 2007, 369, 1261-1269.	6.3	580
6	Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. <i>Lancet</i> , The, 2007, 369, 1169-1178.	6.3	506
7	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 355-365.	13.9	498
8	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2007, 370, 39-48.	6.3	437
9	Comparison of Changes in Bone Density and Turnover with Abacavir+Lamivudine versus Tenofovir+Emtricitabine in HIV-1 Infected Adults: 48-Week Results from the ASSERT Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 963-972.	2.9	370
10	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. <i>Lancet</i> , The, 2011, 378, 238-246.	6.3	361
11	A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1995, 333, 408-413.	13.9	326
12	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. <i>Lancet</i> , The, 2006, 368, 466-475.	6.3	326
13	Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 1442-1455.	13.9	320
14	Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 36, 1011-1019.	0.9	288
15	The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. <i>Aids</i> , 2007, 21, 1273-1281.	1.0	287
16	Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 740-748.	1.9	271
17	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. <i>Lancet</i> , The, 2017, 390, 2063-2072.	6.3	253
18	Diagnosis of central nervous system complications in HIV-infected patients. <i>Aids</i> , 1997, 11, 1-17.	1.0	239

#	ARTICLE	IF	CITATIONS
19	Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. <i>Aids</i> , 1998, 12, 1327-1332.	1.0	226
20	The Efficiency of Male-to Female and Female-to-Male Sexual Transmission of the Human Immunodeficiency Virus. <i>Epidemiology</i> , 1994, 5, 570-575.	1.2	224
21	Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 39-48.	0.9	211
22	Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. <i>Aids</i> , 2005, 19, 685-694.	1.0	208
23	Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line. <i>Blood</i> , 1998, 91, 258-265.	0.6	205
24	Long-term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612.	2.9	196
25	96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. <i>Aids</i> , 2006, 20, 711-718.	1.0	188
26	A Controlled Study of Inhaled Pentamidine for Primary Prevention of <i>Pneumocystis carinii</i> Pneumonia. <i>New England Journal of Medicine</i> , 1991, 324, 1079-1083.	13.9	185
27	Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. <i>Aids</i> , 1996, 10, 951-958.	1.0	184
28	Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus-Infected Women: Effect of Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2001, 184, 547-551.	1.9	182
29	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. <i>Lancet HIV</i> , 2015, 2, e127-e136.	2.1	180
30	Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. <i>Aids</i> , 2009, 23, 2289-2300.	1.0	164
31	Mother-to-Child Transmission of Hepatitis C Virus Detected by Nested Polymerase Chain Reaction. <i>Journal of Infectious Diseases</i> , 1992, 165, 720-723.	1.9	161
32	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. <i>Aids</i> , 1994, 8, 757-762.	1.0	159
33	Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 404-412.	0.9	151
34	Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRK. <i>Clinical Infectious Diseases</i> , 2011, 53, 807-816.	2.9	149
35	Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 2019-2035.	0.5	146
36	Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results. <i>Clinical Infectious Diseases</i> , 2007, 44, 1484-1492.	2.9	143

#	ARTICLE	IF	CITATIONS
37	Prognostic Significance of JC Virus DNA Levels in Cerebrospinal Fluid of Patients with HIV-Associated Progressive Multifocal Leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 2005, 40, 738-744.	2.9	142
38	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). <i>Aids</i> , 2006, 20, 795-803.	1.0	139
39	Progressive Multifocal Leukoencephalopathy (PML) Development Is Associated With Mutations in JC Virus Capsid Protein VP1 That Change Its Receptor Specificity. <i>Journal of Infectious Diseases</i> , 2011, 204, 103-114.	1.9	135
40	Dolutegravir in antiretroviral-naive adults with HIV-1. <i>Aids</i> , 2013, 27, 1771-1778.	1.0	134
41	A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 1251-1260.	1.9	132
42	Highly Active Antiretroviral Therapy and Progressive Multifocal Leukoencephalopathy: Effects on Cerebrospinal Fluid Markers of JC Virus Replication and Immune Response. <i>Clinical Infectious Diseases</i> , 2000, 30, 95-99.	2.9	126
43	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 22, 369.	0.9	122
44	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 587-596.	4.6	119
45	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 565-571.	2.9	118
46	The Effect of Highly Active Antiretroviral Therapy-Induced Immune Reconstitution on Development and Outcome of Progressive Multifocal Leukoencephalopathy: Study of 43 Cases with Review of the Literature. <i>Journal of NeuroVirology</i> , 2003, 9, 73-80.	1.0	117
47	Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. <i>Aids</i> , 2013, 27, 939-950.	1.0	117
48	Antigen-driven C $\alpha$ C Chemokine-mediated HIV-1 Suppression by CD4+ T Cells from Exposed Uninfected Individuals Expressing the Wild-type CCR-5 Allele. <i>Journal of Experimental Medicine</i> , 1997, 186, 455-460.	4.2	116
49	Cerebrospinal fluid HIV-1 RNA levels. <i>Aids</i> , 1998, 12, 389-394.	1.0	116
50	Real-Time PCR Assay for Clinical Management of Human Immunodeficiency Virus-Infected Patients with Visceral Leishmaniasis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5080-5084.	1.8	115
51	CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro. <i>Journal of Immunology</i> , 2000, 164, 3426-3433.	0.4	114
52	The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2001, 7, 358-363.	1.0	112
53	Gender Differences in Antiretroviral Drug-Related Adipose Tissue Alterations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 58-61.	0.9	111
54	Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2002, 109, 681-688.	3.9	109

#	ARTICLE	IF	CITATIONS
55	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> , 2017, 4, e536-e546.	2.1	101
56	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4A: a phase 2 randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , 2014, 14, 291-300.	4.6	100
57	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 1741-1751.	1.0	99
58	Analysis of HIV-1 and CMV-specific memory CD4 T-cell responses during primary and chronic infection. <i>Blood</i> , 2002, 100, 1381-1387.	0.6	97
59	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	1.1	94
60	Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir. <i>Journal of Infectious Diseases</i> , 2011, 204, 1811-1815.	1.9	94
61	Parenteral and Sexual Transmission of Human Immunodeficiency Virus in Intravenous Drug Users: A Study of Seroconversion. <i>American Journal of Epidemiology</i> , 1992, 135, 225-233.	1.6	91
62	Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial. <i>Clinical Infectious Diseases</i> , 2006, 43, 1347-1356.	2.9	85
63	Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3253-3259.	1.4	83
64	Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 413-421.	0.9	83
65	Varicella-Zoster Virus (VZV) DNA in Cerebrospinal Fluid of Patients Infected with Human Immunodeficiency Virus: VZV Disease of the Central Nervous System or Subclinical Reactivation of VZV Infection?. <i>Clinical Infectious Diseases</i> , 1997, 25, 634-639.	2.9	79
66	Rapid Diagnosis of Mycobacterial Infections and Quantitation of Mycobacterium tuberculosis Load by Two Real-Time Calibrated PCR Assays. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4565-4572.	1.8	79
67	Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection. <i>Blood</i> , 1999, 94, 4202-4209.	0.6	77
68	Herpes Simplex Virus Infections of the Central Nervous System in Human Immunodeficiency Virus-Infected Patients: Clinical Management by Polymerase Chain Reaction Assay of Cerebrospinal Fluid. <i>Clinical Infectious Diseases</i> , 1998, 27, 303-309.	2.9	74
69	Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 284, E274-E280.	1.8	74
70	Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. <i>European Journal of Epidemiology</i> , 2012, 27, 657-665.	2.5	73
71	Man-to-Woman Sexual Transmission of the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 1991, 151, 2411.	4.3	72
72	Shorter Survival of SDF1 $\beta$ /3 Homozygotes Linked to CD4+T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2000, 182, 311-315.	1.9	70

#	ARTICLE	IF	CITATIONS
73	Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. <i>Journal of NeuroVirology</i> , 2002, 8, 432-438.	1.0	70
74	Factors Associated with the Development of Opportunistic Infections in HIV-1 Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 633-641.	1.9	70
75	Plasma levels of soluble CD30, tumour necrosis factor (TNF)- $\alpha$ and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. <i>Aids</i> , 1996, 10, F45-F50.	1.0	68
76	Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. <i>Blood</i> , 2006, 107, 4825-4833.	0.6	66
77	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. <i>Aids</i> , 2009, 23, 455-460.	1.0	66
78	Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2002, 109, 681-688.	3.9	65
79	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1887-1897.	1.0	64
80	Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide. <i>Aids</i> , 2004, 18, 1137-1146.	1.0	64
81	JC polyomavirus mutants escape antibody-mediated neutralization. <i>Science Translational Medicine</i> , 2015, 7, 306ra151.	5.8	64
82	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. <i>Lancet HIV</i> , 2017, 4, e195-e204.	2.1	64
83	CCR2 Polymorphism and HIV Disease. <i>Nature Medicine</i> , 1998, 4, 252-253.	15.2	63
84	Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 456-463.	0.9	62
85	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395.	1.0	61
86	Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 268-280.	0.9	60
87	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. <i>Vaccine</i> , 2009, 27, 3306-3312.	1.7	59
88	Ganciclovir Is Associated with Low or Undetectable Epstein-Barr Virus DNA Load in Cerebrospinal Fluid of Patients with HIV-Related Primary Central Nervous System Lymphoma. <i>Clinical Infectious Diseases</i> , 2006, 42, e21-e25.	2.9	58
89	The Appealing Story of HIV Entry Inhibitors. <i>Drugs</i> , 2005, 65, 879-904.	4.9	57
90	The natural history of HIV infection in intravenous drug users. <i>Aids</i> , 1989, 3, 87-90.	1.0	56

#	ARTICLE	IF	CITATIONS
91	The preventive phase I trial with the HIV-1 Tat-based vaccine. <i>Vaccine</i> , 2009, 28, 371-378.	1.7	56
92	Predictors of Virological Outcome and Safety in Primary HIV Type 1-Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. <i>Clinical Infectious Diseases</i> , 2007, 45, 381-390.	2.9	55
93	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	0.9	55
94	Polymerase chain reaction for <i>Toxoplasma gondii</i> DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. <i>Aids</i> , 1994, 8, 1691-1694.	1.0	54
95	Expression of CD4 on human peripheral blood neutrophils. <i>Blood</i> , 2003, 101, 4452-4456.	0.6	54
96	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 425-433.	1.3	53
97	Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. <i>Aids</i> , 2003, 17, 2291-2298.	1.0	52
98	Changes in use of antiretroviral therapy in regions of Europe over time. <i>Aids</i> , 1998, 12, 2031-2039.	1.0	51
99	The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. <i>Aids</i> , 2008, 22, 2207-2209.	1.0	51
100	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	1.0	51
101	Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. <i>Aids</i> , 1999, 13, 791-796.	1.0	50
102	Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. <i>Aids</i> , 1995, 9, 597-604.	1.0	49
103	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. <i>Aids</i> , 2001, 15, 201-209.	1.0	48
104	Efficacy of Low-dose Intermittent Subcutaneous Interleukin (IL)-2 in Antiviral Drug-Experienced Human Immunodeficiency Virus-Infected Persons with Detectable Virus Load: A Controlled Study of 3 IL-2 Regimens with Antiviral Drug Therapy. <i>Journal of Infectious Diseases</i> , 2001, 183, 1476-1484.	1.9	48
105	Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. <i>Aids</i> , 2003, 17, 1993-1995.	1.0	48
106	Atazanavir: A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials. <i>Journal of the International Association of Providers of AIDS Care</i> , 2004, 3, 92-98.	1.2	48
107	TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2007, 21, 533-543.	1.1	48
108	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	0.9	48

#	ARTICLE	IF	CITATIONS
109	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	2.9	48
110	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 324-333.	0.9	46
111	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 369.	0.9	45
112	The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated <i>Toxoplasma gondii</i> encephalitis in patients with AIDS. <i>Journal of Medical Microbiology</i> , 2002, 51, 879-890.	0.7	45
113	Access denied? The status of co-receptor inhibition to counter HIV entry. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 923-933.	0.9	43
114	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. <i>Aids</i> , 2010, 24, 924-928.	1.0	43
115	Infection of Circulating CD34+ Cells by HHV-8 in Patients with Kaposi's Sarcoma. <i>Journal of Investigative Dermatology</i> , 1999, 113, 613-616.	0.3	42
116	Anti-Cell Antibodies in Exposed Seronegative Individuals with HIV Type 1-Neutralizing Activity. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 109-115.	0.5	42
117	Selected Pool of Peptides from ESAT-6 and CFP-10 Proteins for Detection of <i>Mycobacterium tuberculosis</i> Infection. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3469-3474.	1.8	42
118	Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. <i>Journal of Neurology</i> , 1999, 246, 723-725.	1.8	41
119	Virological and Immunological Effects of Combination Antiretroviral Therapy with Zidovudine, Lamivudine, and Indinavir during Primary Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2000, 182, 950-954.	1.9	41
120	Effect of Genotypic Resistance on the Virological Response to Highly Active Antiretroviral Therapy in Cerebrospinal Fluid. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 377-383.	0.5	41
121	Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-positive individuals: 96 week results from FLAMINGO. <i>Journal of the International AIDS Society</i> , 2014, 17, 19490.	1.2	41
122	Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. <i>Journal of Clinical Investigation</i> , 2000, 105, 777-782.	3.9	41
123	Pretreatment of Chronic Active Hepatitis C in Patients Coinfected With HIV and Hepatitis C Virus Reduces the Hepatotoxicity Associated With Subsequent Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 146-152.	0.9	40
124	The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. <i>Annals of Neurology</i> , 2004, 55, 687-694.	2.8	40
125	Positive modification of injecting behavior among intravenous heroin users from Milan and Northern Italy 1987-1989. <i>Addiction</i> , 1991, 86, 91-102.	1.7	39
126	Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5 $\Delta$ 32) genotype is neither essential nor sufficient for protection against disease progression. <i>European Journal of Immunology</i> , 1997, 27, 3223-3227.	1.6	39



#	ARTICLE	IF	CITATIONS
127	Enfuvirtide: the first HIV fusion inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 453-464.	0.9	39
128	Liver Fibrosis in HIV-Positive Patients With Hepatitis C Virus. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 63-67.	0.9	39
129	Cytomegalovirus Pneumonia in AIDS Patients. <i>Chest</i> , 1998, 113, 919-923.	0.4	38
130	Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. <i>Aids</i> , 2000, 14, 2257-2263.	1.0	38
131	Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor $\beta$ chain repertoire and reduces the level of T-cell oligoclonality. <i>Blood</i> , 2000, 95, 1743-1751.	0.6	38
132	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875.	1.0	38
133	Antiretroviral Treatment Strategies and Immune Reconstitution in Treatment-naive HIV-Infected Patients with Advanced Disease. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, S19-S30.	0.9	38
134	Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2008, 80, 766-771.	2.5	38
135	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 759-765.	0.7	38
136	Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. <i>Aids</i> , 2000, 14, 1656-1658.	1.0	38
137	CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. <i>Blood</i> , 2004, 104, 2205-2206.	0.6	37
138	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. <i>Aids</i> , 2008, 22, 2187-2198.	1.0	37
139	Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. <i>Aids</i> , 2007, 21, 13-22.	1.0	36
140	Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. <i>Blood</i> , 2007, 109, 5380-5389.	0.6	36
141	Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 25, 56-62.	0.9	35
142	Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. <i>Antiviral Therapy</i> , 2010, 15, 993-1002.	0.6	35
143	Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1. <i>Aids</i> , 2014, 28, 717-725.	1.0	35
144	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010, 33, 195-206.	0.1	35

#	ARTICLE	IF	CITATIONS
145	Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. <i>Aids</i> , 2001, 15, 2423-2429.	1.0	34
146	Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. <i>European Journal of Endocrinology</i> , 2007, 156, 503-509.	1.9	34
147	An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 307-314.	0.7	34
148	Cytokines and Soluble Receptor Changes in the Transition from Primary to Early Chronic HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 325-331.	0.5	33
149	The Binding Subunit of Pertussis Toxin Inhibits HIV Replication in Human Macrophages and Virus Expression in Chronically Infected Promonocytic U1 Cells. <i>Journal of Immunology</i> , 2001, 166, 1863-1870.	0.4	33
150	Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. <i>Aids</i> , 2005, 19, 153-162.	1.0	33
151	Monocyte-derived macrophage function in HIV-infected subjects: In vitro modulation by rIFN- $\beta$ and rGM-CSF. <i>Clinical Immunology and Immunopathology</i> , 1992, 62, 176-182.	2.1	32
152	Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. <i>Journal of Neuroimmunology</i> , 2004, 157, 133-139.	1.1	32
153	Determination of Human Papillomavirus (HPV) Load and Type in High-Grade Cervical Lesions Surgically Resected from HIV-Infected Women during Follow-up of HPV Infection. <i>Clinical Infectious Diseases</i> , 2005, 40, 451-457.	2.9	32
154	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. <i>Aids</i> , 1995, 9, 691-694.	1.0	31
155	Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial. <i>HIV Clinical Trials</i> , 2017, 18, 135-140.	2.0	31
156	How Many HIV-Infected Individuals May Be Defined as Long-term Nonprogressors? A Report from the Italian Seroconversion Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 243-248.	0.3	31
157	HIV-related severe thrombocytopenia in intravenous drug users. <i>Aids</i> , 1990, 4, 29-34.	1.0	30
158	Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies. <i>Aids</i> , 1993, 7, 167-174.	1.0	30
159	Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1 Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. <i>HIV Clinical Trials</i> , 2012, 13, 228-232.	2.0	30
160	A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers. <i>BMC Infectious Diseases</i> , 2017, 17, 61.	1.3	30
161	Recovery of HIV-related Retroviruses From Italian Patients with AIDS or AIDS-related Complex and from Asymptomatic At-Risk Individuals. <i>Annals of the New York Academy of Sciences</i> , 1987, 511, 390-400.	1.8	29
162	Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. <i>Aids</i> , 1993, 7, 209-212.	1.0	29

#	ARTICLE	IF	CITATIONS
163	Ten-year survival among HIV-infected subjects with AIDS or non-AIDS-defining malignancies. <i>International Journal of Cancer</i> , 2012, 130, 2990-2996.	2.3	29
164	HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. <i>Immunology Letters</i> , 1996, 51, 39-43.	1.1	28
165	Detection of Hepatitis C Mutants With Natural Resistance to NS3/4A Protease Inhibitors in HIV/HCV-Coinfected Individuals Treated With Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 51, 106-108.	0.9	28
166	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105893.	1.1	28
167	Acute Pancreatitis during Primary HIV-1 Infection. <i>New England Journal of Medicine</i> , 1997, 336, 1836-1837.	13.9	27
168	The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 495-501.	1.1	27
169	Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2005, 19, S151-S165.	1.0	27
170	Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 429-440.	0.9	27
171	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2525-2532.	1.3	27
172	Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women. , 1998, 56, 133-137.		26
173	Detection of Rifampin Resistance in <i>Mycobacterium tuberculosis</i> by Double Gradient-Denaturing Gradient Gel Electrophoresis. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2550-2554.	1.4	26
174	Comparison of Three Nucleic Acid Amplification Assays of Cerebrospinal Fluid for Diagnosis of Cytomegalovirus Encephalitis. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1148-1151.	1.8	26
175	Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals. <i>Aids</i> , 2002, 16, 1003-1008.	1.0	26
176	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 213-217.	1.3	26
177	Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. <i>Antiviral Therapy</i> , 2009, 14, 339-347.	0.6	26
178	Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 216-223.	0.5	25
179	A Mobile Application for Exercise Intervention in People Living with HIV. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 425-433.	0.2	25
180	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25

#	ARTICLE	IF	CITATIONS
181	Screening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in Italy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 37, 1295-1306.	0.9	24
182	Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 <sup>bright</sup> subset. <i>Immunology</i> , 2010, 129, 220-233.	2.0	24
183	Clinical and immunological aspects of HIV infection in drug addicts. <i>Clinical Immunology and Immunopathology</i> , 1989, 50, S166-S176.	2.1	23
184	Double-edged effect of VÎ³9/VÎ²2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. <i>European Journal of Immunology</i> , 2003, 33, 252-263.	1.6	23
185	In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. <i>Clinical Immunology</i> , 2003, 109, 355-358.	1.4	23
186	Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage. <i>Antiviral Therapy</i> , 2011, 16, 1035-1045.	0.6	23
187	Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations. <i>HIV Clinical Trials</i> , 2006, 7, 86-96.	2.0	22
188	NF-Î²B Modulates Sensitivity to Apoptosis, Proinflammatory and Migratory Potential in Short- versus Long-Term Cultured Human Î³Î³ Lymphocytes. <i>Journal of Immunology</i> , 2008, 181, 5857-5864.	0.4	22
189	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression. <i>Aids</i> , 2014, 28, 2269-2279.	1.0	22
190	Bictegravir. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 326-333.	1.5	22
191	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 177-182.	1.3	22
192	Isolation of spindle-shaped cell populations from primary cultures of Kaposi's sarcoma of different stage. <i>Cancer Letters</i> , 1996, 100, 125-132.	3.2	21
193	Anti-CD4 Antibodies in Exposed Seronegative Adults and in Newborns of HIV Type 1-Seropositive Mothers: A Follow-up Study. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1079-1085.	0.5	21
194	Detection of <i>Pneumocystis carinii</i> and Characterization of Mutations Associated with Sulfa Resistance in Bronchoalveolar Lavage Samples from Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2709-2712.	1.8	21
195	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004, 10, 52-57.	1.0	21
196	Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. <i>Aids</i> , 2007, 21, 1648-1651.	1.0	21
197	Lopinavir/ritonavir + tenofovir Dual Therapy versus Lopinavir/ritonavir-Based Triple Therapy in HIV-Infected Antiretroviral Naïve Subjects: The Kalead Study. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2010, 02, .	0.1	21
198	A simplified flow cytometry method of CD4 and CD8 cell counting based on thermoresistant reagents: Implications for large scale monitoring of HIV-infected patients in resource-limited settings. <i>Cytometry Part B - Clinical Cytometry</i> , 2005, 68B, 43-51.	0.7	20

#	ARTICLE	IF	CITATIONS
199	The effects of the Roche AMPLICOR HIV-1 MONITORÂ® UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. <i>Journal of Clinical Virology</i> , 2006, 35, 420-425.	1.6	20
200	Darunavir for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1149-1163.	0.9	20
201	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2011, 34, 109-46.	0.1	20
202	The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen. <i>Antiviral Therapy</i> , 2004, 9, 537-543.	0.6	20
203	Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. <i>Aids</i> , 2003, 17, 2136-2138.	1.0	19
204	GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. <i>European Journal of Endocrinology</i> , 2005, 153, 781-789.	1.9	19
205	An In-House RD1-Based Enzyme-Linked Immunospot-Gamma Interferon Assay Instead of the Tuberculin Skin Test for Diagnosis of Latent Mycobacterium tuberculosis Infection. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1944-1950.	1.8	19
206	Durability and Safety of a Novel Salvage Therapy in R5-Tropic HIV-Infected Patients: Maraviroc, Raltegravir, Etravirine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e113-e115.	0.9	19
207	Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-NaÃve HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, , 1.	0.9	19
208	Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters. <i>Perfusion (United Kingdom)</i> , 2002, 17, 47-51.	0.5	18
209	Successful voriconazole therapy of disseminated <i>Fusarium verticillioides</i> infection in an immunocompromised patient receiving chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 796-798.	1.3	18
210	Viro-Immunologic Response to Ritonavir-Boosted or Unboosted Atazanavir in a Large Cohort of Multiply Treated Patients: The CARE Study. <i>AIDS Patient Care and STDs</i> , 2008, 22, 7-16.	1.1	18
211	Long-Term Remission of HIV-Associated Primary CNS Lymphoma Achieved With Highly Active Antiretroviral Therapy Alone. <i>Journal of Clinical Oncology</i> , 2012, 30, e119-e121.	0.8	18
212	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008, 80, 201-208.	2.5	17
213	Rheumatoid factors and circulating immune complexes in HIV-infected individuals. <i>Aids</i> , 1991, 5, 1441-1446.	1.0	16
214	Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1151-1153.	0.5	16
215	Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIVâ1 infected patients failing HAART. <i>Journal of Medical Virology</i> , 2008, 80, 1695-1706.	2.5	16
216	Predicting the magnitude of short-term CD4<sup>+</sup> T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 165-175.	0.6	16

#	ARTICLE	IF	CITATIONS
217	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. <i>Aids</i> , 2014, 28, 2407-2415.	1.0	16
218	Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 103-111.	0.5	16
219	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa456.	0.4	16
220	Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. <i>HIV Clinical Trials</i> , 2017, 18, 118-125.	2.0	16
221	Spatial Working Memory in Asymptomatic HIV-Infected Subjects. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 387-391.	0.9	15
222	CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and in lymphocytes. <i>European Journal of Immunology</i> , 2003, 33, 3136-3145.	1.6	15
223	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 831-836.	1.3	15
224	Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1-Infected, Treatment-Naïve ARTEMIS Patients at Week 96. <i>HIV Clinical Trials</i> , 2011, 12, 313-322.	2.0	15
225	Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program. <i>HIV Clinical Trials</i> , 2012, 13, 83-89.	2.0	15
226	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. <i>BMC Infectious Diseases</i> , 2017, 17, 43.	1.3	15
227	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
228	Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males. <i>PLoS ONE</i> , 2017, 12, e0186367.	1.1	15
229	Acute ataxia coincident with seroconversion for anti-HIV. <i>Journal of Neurology</i> , 1991, 238, 356-357.	1.8	14
230	Î²-Endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. <i>Peptides</i> , 1994, 15, 769-775.	1.2	14
231	Human Immunodeficiency Virus Type 1 Glycoprotein 120-Specific T Lymphocytes Provide Intermolecular Help for Anti-CD4 Autoantibody Production in Exposed Uninfected Subjects. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 1461-1469.	0.5	14
232	Dual role of TNF-Î± in NK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. <i>European Journal of Immunology</i> , 1999, 29, 3654-3662.	1.6	14
233	Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3155-3157.	1.4	14
234	Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. <i>Aids</i> , 2001, 15, 1109-1113.	1.0	14

#	ARTICLE	IF	CITATIONS
235	Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naïve HIV-infected patients. <i>Aids</i> , 2005, 19, 473-479.	1.0	14
236	Comparison of an In-house and a Commercial RD1-based ELISPOT-IFN- $\gamma$ Assay for the Diagnosis of Mycobacterium tuberculosis Infection. <i>Clinical Medicine and Research</i> , 2006, 4, 266-272.	0.4	14
237	Recombinant Human Growth Hormone. <i>BioDrugs</i> , 2008, 22, 101-112.	2.2	14
238	Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: Modes of response and correlation with markers of HIV replication. <i>European Journal of Haematology</i> , 1993, 50, 17-21.	1.1	14
239	Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naïve Patients With Recent Diagnosis of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e51-e53.	0.9	14
240	Human immunodeficiency virus (HIV) seropositivity in intravenous (IV) drug abusers in three cities of Italy: Possible natural history of HIV infection in IV drug addicts in Italy. <i>Journal of Medical Virology</i> , 1987, 23, 241-248.	2.5	13
241	Detection of DNA of Lymphotropic Herpesviruses in Plasma of Human Immunodeficiency Virus-Infected Patients: Frequency and Clinical Significance. <i>Vaccine Journal</i> , 2002, 9, 1222-1228.	3.2	13
242	Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in Italy. <i>HIV Clinical Trials</i> , 2005, 6, 92-102.	2.0	13
243	Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: Possible protective effect of infecting HCV genotype on HIV disease progression. <i>Journal of Clinical Virology</i> , 2007, 39, 82-86.	1.6	13
244	Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 901-911.	1.3	13
245	Central Nervous System HIV Infection in "Less-Drug Regimen" Antiretroviral Therapy Simplification Strategies. <i>Seminars in Neurology</i> , 2014, 34, 078-088.	0.5	13
246	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. <i>New Microbiologica</i> , 2016, 39, 93-109.	0.1	13
247	Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 1253-1258.	2.4	12
248	Direct Detection of Helicobacter pylori Mutations Associated with Macrolide Resistance in Gastric Biopsy Material Taken from Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2234-2237.	1.8	12
249	Neurobrucellosis with spinal cord abscess of the dorsal tract: a case report. <i>International Journal of Infectious Diseases</i> , 2002, 6, 149-150.	1.5	12
250	Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. <i>Aids</i> , 2003, 17, 2669-2671.	1.0	12
251	Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 545-549.	0.8	12
252	Significant link between sCD30 changes and HIV viremia in patients treated with HAART. <i>Journal of Medical Virology</i> , 2006, 78, 1513-1519.	2.5	12

#	ARTICLE	IF	CITATIONS
253	Disseminated rhodococcus equi infection in HIV infection despite highly active antiretroviral therapy. BMC Infectious Diseases, 2011, 11, 343.	1.3	12
254	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naïve patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 1686-1688.	1.3	12
255	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Therapeutics and Clinical Risk Management, 2013, 10, 9.	0.9	12
256	Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy. Clinical Infectious Diseases, 2018, 67, 65-72.	2.9	12
257	Pharmacokinetics of Zidovudine in HIV-Positive Patients with Liver Disease. Journal of Clinical Pharmacology, 1994, 34, 782-786.	1.0	11
258	Expression and Activation of a C-Terminal Truncated Isoform of STAT5 (STAT5 <sup>Δ</sup> ) Following Interleukin 2 Administration or AZT Monotherapy in HIV-Infected Individuals. Clinical Immunology, 2001, 99, 75-81.	1.4	11
259	Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission. Journal of Medical Virology, 2001, 64, 476-481.	2.5	11
260	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. Blood, 2002, 100, 1575-1578.	0.6	11
261	Comparison of a Rule-Based Algorithm with a Phenotype-Based Algorithm for the Interpretation of HIV Genotypes in Guiding Salvage Regimens in HIV-Infected Patients by a Randomized Clinical Trial: The Mutations and Salvage Study. Clinical Infectious Diseases, 2006, 42, 1470-1480.	2.9	11
262	Liver Histology in HIV/Hepatitis C-Coinfected and HCV-Monoinfected Patients With Persistently Normal Alanine Aminotransferases. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 107-108.	0.9	11
263	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. Aids, 2012, 26, 1837-1840.	1.0	11
264	Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. Journal of the International AIDS Society, 2015, 18, 20037.	1.2	11
265	The maraviroc expanded access program "safety and efficacy data from an open-label study. HIV Clinical Trials, 2015, 16, 10-21.	2.0	11
266	Effects of hydroxyurea on T cell count changes during primary HIV infection. Aids, 2000, 14, 619-622.	1.0	11
267	Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets. PLoS ONE, 2015, 10, e0140435.	1.1	11
268	CCR2-64I Polymorphism, Syncytium-Inducing Human Immunodeficiency Virus Strains, and Disease Progression. Journal of Infectious Diseases, 2000, 182, 1579-1580.	1.9	10
269	Mortality of HIV-Infected Patients with or without Cancer: Comparison with the General Population in Italy. Antiviral Therapy, 2012, 17, 447-458.	0.6	10
270	Immune recovery and T cell subset analysis during effective treatment with maraviroc. Journal of Antimicrobial Chemotherapy, 2012, 67, 2474-2478.	1.3	10



#	ARTICLE	IF	CITATIONS
271	Noninvasive fibrosis biomarkers "APRI and Forns" are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , 2013, 33, 1113-1120.	1.9	10
272	Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 164-169.	0.3	10
273	Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1391-1395.	1.3	10
274	Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfecting patients. <i>PLoS ONE</i> , 2017, 12, e0181890.	1.1	10
275	Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 492-499.	1.1	10
276	Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy. <i>Epidemiology and Infection</i> , 2020, 148, e19.	1.0	10
277	Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy. <i>Lancet</i> , 1991, 337, 1488.	6.3	9
278	Kappa light chain predominance in serum and cerebrospinal fluid from human immunodeficiency virus type 1 (HIV-1)-infected patients. <i>Journal of Neuroimmunology</i> , 1991, 32, 259-268.	1.1	9
279	Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. <i>Journal of Infection</i> , 1995, 31, 99-105.	1.7	9
280	Molecular Studies of Cerebrospinal Fluid in Human Immunodeficiency Virus Type 1-Associated Opportunistic Central Nervous System Diseases—An Update. <i>Journal of NeuroVirology</i> , 2002, 8, 122-128.	1.0	9
281	Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. <i>Journal of Medical Virology</i> , 2006, 78, 1537-1541.	2.5	9
282	Unexpected dramatic increase in CD4 <sup>+</sup> cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. <i>Journal of Medical Virology</i> , 2008, 80, 937-941.	2.5	9
283	Magnitude and Determinants of CD4 Recovery After HAART Resumption After 1 Cycle of Treatment Interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 588-594.	0.9	9
284	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1932-1934.	1.3	9
285	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 632-633.	1.3	9
286	Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 787-797.	0.9	9
287	Cost-effectiveness analysis of the use of daclatasvir+sofosbuvir+sofosbuvir+sofosbuvir (16 weeks and 12 weeks) vs sofosbuvir+sofosbuvir (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. <i>European Journal of Health Economics</i> , 2018, 19, 37-44.	1.4	9
288	Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. <i>PLoS ONE</i> , 2017, 12, e0182007.	1.1	9

#	ARTICLE	IF	CITATIONS
289	TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. <i>World Journal of Gastroenterology</i> , 2016, 22, 8509.	1.4	9
290	Tumor Necrosis Factor $\alpha$ , Interleukin 2, and Soluble Interleukin 2 Receptor Levels in Human Immunodeficiency Virus Type 1-Infected Individuals Receiving Intermittent Cycles of Interleukin 2. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 491-499.	0.5	8
291	Oral CCR5 inhibitors: will they make it through?. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 451-464.	1.9	8
292	The 118I Reverse Transcriptase Mutation Is the Only Independent Genotypic Predictor of Virologic Failure to a Stavudine-Containing Salvage Therapy in HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 447-452.	0.9	8
293	Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 192-195.	0.9	8
294	Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. <i>Medicine (United States)</i> , 2015, 94, e1876.	0.4	8
295	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1637-1642.	1.3	8
296	Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 617-623.	0.9	8
297	HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy. <i>Infection</i> , 2020, 48, 553-558.	2.3	8
298	Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection. <i>Aids</i> , 2000, 14, 1861-1862.	1.0	8
299	Thymostimulin treatment in AIDS-related complex. <i>Clinical Immunology and Immunopathology</i> , 1988, 47, 253-261.	2.1	7
300	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. <i>Aids</i> , 2004, 18, 2205-2208.	1.0	7
301	Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2004, 72, 181-186.	2.5	7
302	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 384-387.	1.3	7
303	Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 409.	0.7	7
304	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw492.	1.3	7
305	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 415-417.	1.8	7
306	The use of circulating cathodic antigen rapid test and serology for diagnosis of active <i>Schistosoma mansoni</i> infection in migrants in Italy, a non-endemic country: a cross sectional study. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017, 112, 452-455.	0.8	7

#	ARTICLE	IF	CITATIONS
307	A Randomized Controlled Study for the Evaluation of the Activity of a Triple Combination of Zidovudine, Thymosin- $\alpha$ 1 and Interferon- $\alpha$ 2 in HIV-Infected Individuals with CD4 Counts between 200 and 500 cells/mm <sup>3</sup> . <i>Antiviral Therapy</i> , 1998, 3, 103-111.	0.6	7
308	Sequencing antiretroviral drugs for long-lasting suppression of HIV replication. <i>New Microbiologica</i> , 2005, 28, 281-97.	0.1	7
309	No Protective Effect of Acyclovir on HIV Disease Progression in a Cohort of Hsv-2-Infected Individuals. <i>Antiviral Therapy</i> , 2002, 7, 289-291.	0.6	7
310	Pulmonary Candidiasis in a Heroin Addict: Some Remarks on its Aetiology and Pathogenesis. <i>Addiction</i> , 1985, 80, 103-104.	1.7	6
311	Hepatitis C virus infection in blood donors with indeterminate results in second-generation recombinant immunoblot assay. <i>Transfusion</i> , 1994, 34, 555-556.	0.8	6
312	Modeling Incidence Rate Ratio and Rate Difference: Additivity or Multiplicativity of Human Immunodeficiency Virus Parenteral and Sexual Transmission among Intravenous Drug Users. <i>American Journal of Epidemiology</i> , 1995, 141, 16-24.	1.6	6
313	Temporal Lobe Electroencephalogram Power Modifications during Olfactory Stimulation in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 547-551.	0.5	6
314	Favorable outcome of ex vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1. <i>Journal of Medical Virology</i> , 2007, 79, 1640-1649.	2.5	6
315	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. <i>Medicine (United States)</i> , 2016, 95, e3780.	0.4	6
316	Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. <i>Medicine (United States)</i> , 2016, 95, e3780.	0.4	6
317	NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B. <i>Archives of Virology</i> , 2017, 162, 2271-2277.	0.9	6
318	Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 381-393.	0.3	6
319	Lymph Node Finding in Drug Abusers. <i>American Journal of Clinical Pathology</i> , 1984, 82, 749-750.	0.4	5
320	Maternal predictors of HIV vertical transmission. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1991, 42, 131-136.	0.5	5
321	Lack of immune recovery in HIV/Leishmania co-infection treated with human recombinant IL-2. <i>Aids</i> , 2007, 21, 1223-1225.	1.0	5
322	Raltegravir in treatment naïve patients. <i>European Journal of Medical Research</i> , 2009, 14, 22.	0.9	5
323	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load $\leq$ 50 copies/mL in the observational setting. <i>Antiviral Therapy</i> , 2013, 19, 319-324.	0.6	5
324	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1436-1439.	1.3	5

#	ARTICLE	IF	CITATIONS
325	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , 2017, 17, 723.	1.3	5
326	Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. <i>Aids</i> , 2000, 14, 1664-1667.	1.0	5
327	Structural skull defects in type IV Ehlers-Danlos syndrome. <i>British Journal of Dermatology</i> , 1984, 110, 122-124.	1.4	4
328	Human Immunodeficiency Virus gp120 and p24 Oligoclonal Antibody in Acquired Immunodeficiency Syndrome Cerebrospinal Fluid and Sera. <i>Annals of the New York Academy of Sciences</i> , 1988, 540, 611-614.	1.8	4
329	Transitory Expansion of a CD3 <sup>+</sup> TcR <sup>β</sup> <sup>+</sup> CD16 <sup>+</sup> Lymphocytic Population in Two Patients with Advanced Human Immunodeficiency Virus Infection and High Levels of Natural Killer Activity. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 711-715.	0.5	4
330	Serum Polymerase Chain Reaction for Cytomegalovirus DNA for Monitoring Ganciclovir Treatment in AIDS Patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1996, 28, 347-351.	1.5	4
331	Ex Vivo Modulation of RANTES and sCD30 by Proinflammatory Stimuli in HIV-Seropositive and -Negative Individuals. <i>Clinical Immunology</i> , 2000, 97, 102-108.	1.4	4
332	Redistribution of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors after a Protease Inhibitor-Sparing Regimen. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 545-554.	0.5	4
333	Immunological Basis for IgE Hyper-Production in Enfuvirtide-Treated HIV- Positive Patients. <i>Journal of Clinical Immunology</i> , 2006, 26, 168-176.	2.0	4
334	Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 179-184.	0.9	4
335	A Step Ahead on the HIV Collaboratory. <i>Science</i> , 2009, 324, 1264-1265.	6.0	4
336	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010, 47, 253-257.	1.6	4
337	Monotherapy With Atazanavir as a Simplificati Strategy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, e101-e103.	0.9	4
338	Susacâ€™s syndrome as HIV-associated immune reconstitution inflammatory syndrome. <i>AIDS Research and Therapy</i> , 2013, 10, 22.	0.7	4
339	Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2960-2963.	1.3	4
340	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19806.	1.2	4
341	Optimal dietary calcium intake in HIV treated patients: No femoral osteoporosis but higher cardiovascular risk. <i>Clinical Nutrition</i> , 2014, 33, 363-366.	2.3	4
342	Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. <i>PLoS ONE</i> , 2018, 13, e0191300.	1.1	4

#	ARTICLE	IF	CITATIONS
343	Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). <i>New Microbiologica</i> , 2016, 39, 290-294.	0.1	4
344	Diagnosis of Virus-associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid. <i>Annals of the New York Academy of Sciences</i> , 1994, 724, 170-172.	1.8	3
345	Management Strategies for Herpesvirus Infections of the CNS. <i>CNS Drugs</i> , 2000, 14, 95-113.	2.7	3
346	Immunovirological improvement in partially HAART responder HIV-infected patients by monocyte adsorption apheresis. <i>Journal of Clinical Apheresis</i> , 2001, 16, 35-36.	0.7	3
347	Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile. <i>Future Virology</i> , 2007, 2, 131-143.	0.9	3
348	In Vivo Treatment with Fusion Inhibitor Enfuvirtide Leads to Increased IL-12 Production by Autologous in Vitro Activated Monocytes from HIV-infected Individuals. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2009, 01, 043-050.	0.1	3
349	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-infected patients. <i>Cancer</i> , 2013, 119, 2710-2719.	2.0	3
350	Dolutegravir: a new option for HIV treatment. <i>Future Virology</i> , 2014, 9, 801-810.	0.9	3
351	Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e27-e29.	0.9	3
352	HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy. <i>PLoS ONE</i> , 2016, 11, e0168399.	1.1	3
353	An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. <i>Infectious Diseases</i> , 2018, 50, 220-222.	1.4	3
354	&lt;p&gt;A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study&lt;p&gt;, <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 477-479.	2.0	3
355	Risk behaviour and HTLV-1 seropositivity in injecting drug users. <i>Addiction</i> , 1990, 85, 686-687.	1.7	2
356	Lack of Reduction of Thymidine Kinase Activity in Stavudine-Treated HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 701-703.	0.5	2
357	Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients. <i>Aids</i> , 2004, 18, 821-823.	1.0	2
358	Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naïve individuals infected with hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1448-1450.	1.3	2
359	Predictors of lack of serological response to syphilis treatment in HIV-infected subjects. <i>Journal of the International AIDS Society</i> , 2014, 17, 19654.	1.2	2
360	Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman. <i>International Journal of Infectious Diseases</i> , 2014, 29, 100-102.	1.5	2

#	ARTICLE	IF	CITATIONS
361	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017, 11, 188-198.	1.9	2
362	Diagnostic and prognostic significance of Î²2-microglobulin during HIV infection. <i>Research in Clinic and Laboratory</i> , 1990, 20, 105-111.	0.3	2
363	Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. <i>New Microbiologica</i> , 2014, 37, 439-48.	0.1	2
364	Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration. <i>Aids</i> , 2003, 17, 1621-1630.	1.0	1
365	A case of HIV-associated fever of unknown origin: deficit of IL-1Î² antagonistic activity and resolution with monocytic granulocyte apheresis. <i>Aids</i> , 2006, 20, 312-313.	1.0	1
366	Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. <i>Aids</i> , 2007, 21, 2366-2367.	1.0	1
367	Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV-1-infected patients?. <i>Cytometry Part B - Clinical Cytometry</i> , 2007, 72B, 433-441.	0.7	1
368	Effects of endurance exercise training on metabolic and inflammatory parameters in HIV-1-infected patients with secondary lipodystrophy and diabetes. <i>Sport Sciences for Health</i> , 2010, 6, 23-25.	0.4	1
369	Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. <i>Journal of the International AIDS Society</i> , 2014, 17, 19811.	1.2	1
370	Immortal time bias. <i>Aids</i> , 2015, 29, 860-861.	1.0	1
371	Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)â€“Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 62, civ902.	2.9	1
372	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infectionâ€”authorsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1549-1550.	1.3	1
373	Benefits of a 12-week physical activity programme on muscle and bone health in people living with HIV. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, , .	2.9	1
374	Risk of human immunodeficiency virus infection in multiple transfused patients. <i>Transfusion</i> , 1987, 27, 217-217.	0.8	0
375	Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine. <i>Clinical Microbiology and Infection</i> , 1997, 3, 629-633.	2.8	0
376	In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. <i>Clinical Immunology</i> , 2003, 109, 355-355.	1.4	0
377	Comparison of IFN-Î±2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a. <i>Aids</i> , 2004, 18, 1080-1082.	1.0	0
378	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004, 10, 52-57.	1.0	0

#	ARTICLE	IF	CITATIONS
379	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004, 10, 52-57.	1.0	0
380	Nitric Oxide Production in HIV-1 Infected Patients Receiving Intermittent Cycles of Interleukin-2 and Antiretrovirals. <i>HIV Clinical Trials</i> , 2004, 5, 146-151.	2.0	0
381	Immunotherapy of HIV Infection: Dendritic Cells as Targets and Tools. , 2007, , 515-540.		0
382	HIV protease inhibitors: present and future. <i>Future Virology</i> , 2011, 6, 571-580.	0.9	0
383	Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. <i>Aids</i> , 2013, 27, 2661-2663.	1.0	0
384	HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications. <i>ISRN Virology</i> , 2014, 2014, 1-6.	0.5	0
385	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. <i>Aids</i> , 2015, 29, 857-859.	1.0	0